Which GLP-1 medicines are approved for type 2 diabetes?
The short answer
Which GLP-1 for type 2 diabetes? Four are FDA-approved to improve glycemic control (blood sugar control) in type 2 diabetes: Mounjaro, Ozempic (injection and tablets), Rybelsus and Trulicity. Mounjaro and Trulicity are approved from age 10, the others for adults. Zepbound, Wegovy, Foundayo and Saxenda are not approved for glycemic control, according to their FDA labels. Your prescriber helps you choose.
Key takeaways
- Mounjaro, Ozempic, Rybelsus and Trulicity are the GLP-1 medicines approved for type 2 diabetes.
- Mounjaro and Trulicity include patients 10 and older. Ozempic and Rybelsus are approved for adults.
- Rybelsus and Ozempic tablets aren't swapped milligram for milligram. Your prescriber sets the new strength.
- On Medicare, a GLP-1 for type 2 diabetes goes through your Part D plan, not the GLP-1 Bridge.
- If you take insulin or a sulfonylurea, ask whether those doses need adjusting when you start.
If you have type 2 diabetes, four of the eight FDA-approved GLP-1 medicines are approved to treat it. The other four are approved for weight and aren’t diabetes medicines on their labels, even where they share a molecule with one that is. This page sets out what each of the four labels says. For every approved use across all eight, see the conditions overview.
The four medicines and the label wording
Each label gives the core use in the same words: an adjunct to diet and exercise to improve glycemic control in type 2 diabetes mellitus. In plain terms, that’s an add-on to diet and exercise to improve blood sugar control. The differences are in who is included and what else the label adds.
- Mounjaro (tirzepatide). Weekly injection. Adults and pediatric patients 10 years of age and older. Also approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for these events.
- Ozempic (semaglutide). Weekly injection or daily tablet. Adults. The injection is also approved to reduce cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline (a falling measure of kidney function), end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. The tablets carry a cardiovascular use for adults at high risk.
- Rybelsus (semaglutide). Daily tablet. Adults. Also approved to reduce cardiovascular risk in adults with type 2 diabetes who are at high risk.
- Trulicity (dulaglutide). Weekly injection. Adults and pediatric patients 10 years of age and older. Also approved to reduce cardiovascular risk in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
For children, the Mounjaro and Trulicity labels both say safety and effectiveness have not been established in pediatric patients less than 10 years of age.
What the labels report for A1C
A1C, also written HbA1c, is a blood test of your average blood sugar over recent months. Each label reports HbA1c results from its own trials. The trials differ in length, in background treatment and in the people enrolled, so the figures below describe each medicine against its own comparator. They aren’t a ranking. Placebo means an inactive treatment.
- Mounjaro. In a 40-week monotherapy trial (the medicine on its own), the label table gives an HbA1c change of -1.8 (5 mg), -1.7 (10 mg) and -1.7 (15 mg), in percentage points, against -0.1 with placebo.
- Ozempic injection. In a 30-week monotherapy trial, HbA1c changed by -1.4% with 0.5 mg and -1.6% with 1 mg versus -0.1% with placebo. In a separate 40-week trial, the change was -2.1% with 2 mg versus -1.9% with 1 mg.
- Rybelsus. In a 26-week monotherapy trial, HbA1c changed by -1.2% with 7 mg and -1.4% with 14 mg versus -0.3% with placebo. The label notes that the 3 mg starting dose is not effective for glycemic control. For Ozempic tablets, the label says effectiveness was established on the basis of the Rybelsus studies.
- Trulicity. Added to metformin, the HbA1c change at 26 weeks was -1.0% with 0.75 mg and -1.2% with 1.5 mg versus 0.1% with placebo. In a 36-week dose-ranging trial added to metformin, the table gives -1.5 (1.5 mg), -1.6 (3 mg) and -1.8 (4.5 mg), in percentage points.
One label does contain a head-to-head trial. The Mounjaro label reports a 40-week study against semaglutide 1 mg in adults also taking metformin. Its table gives an HbA1c change of -2.0, -2.2 and -2.3 for Mounjaro 5 mg, 10 mg and 15 mg, in percentage points, against -1.9 for semaglutide 1 mg.
Tablet or injection?
Mounjaro and Trulicity are weekly injections. Ozempic comes both ways. Rybelsus is a tablet only.
The two semaglutide tablets share a label, and it carries a warning worth knowing: Rybelsus and Ozempic tablets “are not substitutable on a mg-to-mg basis.” If you’re moved from one to the other, your prescriber sets the new strength.
If you also take insulin or a sulfonylurea
The Mounjaro and Ozempic labels both say that when starting the medicine, the prescriber should consider reducing the dose of insulin or of an insulin secretagogue you take with it. A secretagogue, such as a sulfonylurea, makes the body release more insulin. The aim is to reduce the risk of hypoglycemia, or low blood sugar. That adjustment is your prescriber’s to make.
What about the weight-loss brands?
Zepbound, Wegovy, Foundayo and Saxenda are approved for weight reduction, not glycemic control. Several were studied in people with type 2 diabetes, and the labels report those weight results:
- In Zepbound Study 2 (adults with type 2 diabetes), body weight changed by -12.8% with 10 mg and -14.7% with 15 mg at 72 weeks versus -3.2% with placebo.
- In Wegovy Study 3 (adults with type 2 diabetes and a BMI of 27 or more), body weight changed by -9.6% with Wegovy 2.4 mg injection at 68 weeks versus -3.4% with placebo. The Wegovy label states that the injection resulted in less weight reduction in patients with type 2 diabetes than in those without it.
Zepbound contains tirzepatide, as Mounjaro does, and Wegovy contains semaglutide, as Ozempic and Rybelsus do. Each brand has its own label and approved uses.
Foundayo is not approved for type 2 diabetes. Lilly has since submitted Foundayo to FDA for type 2 diabetes, but a submission is not an approval.
Coverage and cost
A type 2 diabetes diagnosis is the most straightforward route to coverage.
Medicare. CMS, which runs Medicare, states that type 2 diabetes is an indication eligible for Part D coverage, and that people with a GLP-1 prescription for a covered indication should keep getting it through their Part D plan. Your cost then depends on the plan’s formulary (its list of covered drugs) and tier. People with type 2 diabetes are not eligible for the Medicare GLP-1 Bridge. The Medicare guide and the Part D costs page explain the rules.
Commercial insurance. If your plan covers the medicine, manufacturer savings cards bring a fill to as little as $25 for Mounjaro and $25 for Ozempic, subject to each card’s terms. The savings card page has the eligibility rules.
No coverage. Self-pay through the manufacturer is $499 a month for Mounjaro, $349 a month for Ozempic at the 1 mg dose, and starts at $389 a month for Trulicity. The cost pages for Mounjaro, Ozempic, Rybelsus and Trulicity have the full detail, and the cheapest path tool works from your own coverage.
Questions for your prescriber
- Does my heart or kidney history point to a medicine whose label includes that use?
- Would a daily tablet or a weekly injection suit me, and does my plan cover both?
- Do my other diabetes medicines need adjusting when I start?
Frequently asked questions
Which GLP-1 medicines are approved for type 2 diabetes?
Mounjaro (tirzepatide), Ozempic (semaglutide injection and tablets), Rybelsus (semaglutide tablets) and Trulicity (dulaglutide). Each label gives the use as an add-on to diet and exercise to improve blood sugar control in type 2 diabetes. Mounjaro and Trulicity include pediatric patients 10 years of age and older, while Ozempic and Rybelsus are approved for adults.
Is Zepbound or Wegovy approved for type 2 diabetes?
No. Neither label lists blood sugar control as an approved use. Both were studied in people who have type 2 diabetes as well as obesity or overweight, and the labels report weight results from those trials. But the approved uses are weight reduction and, for each brand, the additional uses on its own label.
Does Medicare cover a GLP-1 for type 2 diabetes?
CMS, which runs Medicare, states that type 2 diabetes is an indication eligible for Part D coverage. So a GLP-1 prescribed for it goes through your Part D plan under the plan's formulary (its list of covered drugs) and rules. People with type 2 diabetes are not eligible for the Medicare GLP-1 Bridge, which is for weight management only.
Which GLP-1 for type 2 diabetes comes as a pill?
Rybelsus and Ozempic tablets are both once-daily semaglutide tablets approved for adults with type 2 diabetes, on a shared label. The label says the two are not substitutable on a mg-to-mg basis. Foundayo is also a daily tablet, but it's approved for weight reduction and not for type 2 diabetes.
Which is the best GLP-1 for type 2 diabetes?
The labels don't name one, and you can't compare results from separate trials. The choice depends on your A1C, your heart and kidney history, your age, whether you prefer a tablet or an injection, other medicines you take, and what your plan covers. That's a decision for you and your prescriber.
Sources (26)
- 1.Eli Lilly: Eli Lilly and Company Form 10-Q for the quarter ended September 30, 2026
“Submitted orforglipron for type 2 diabetes in the U.S. and Japan.”
- 2.FDA label (DailyMed): Mounjaro prescribing information, section 14.2, Table 4
“Table 4: Results at Week 40 in a Trial of MOUNJARO as Monotherapy in Adult Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control with Diet and Exercise. HbA1c (%) - Change at Week 40: Placebo: -0.1; MOUNJARO 5 mg: -1.8; MOUNJARO 10 mg: -1.7; MOUNJARO 15 mg: -1.7”
- 3.FDA label (DailyMed): Mounjaro prescribing information, section 14.3, Table 5
“Table 5: Results at Week 40 in a Trial of MOUNJARO versus Semaglutide 1 mg in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin. HbA1c (%) - Change at Week 40: Semaglutide 1 mg: -1.9; MOUNJARO 5 mg: -2.0; MOUNJARO 10 mg: -2.2; MOUNJARO 15 mg: -2.3”
- 4.FDA label (DailyMed): Ozempic prescribing information, section 14.1, Table 3
“Monotherapy with OZEMPIC 0.5 mg and 1 mg once weekly for 30 weeks resulted in a statistically significant reduction in HbA1c compared with placebo”
- 5.FDA label (DailyMed): Ozempic prescribing information, section 14.1, Table 7
“The mean changes from baseline to week 40 were -5.6 kg and -6.4 kg in the OZEMPIC 1 mg and OZEMPIC 2 mg arms, respectively. The difference between treatment arms in body weight change from baseline at week 40 was not statistically significant.”
- 6.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 14.2, Table 4
“resulted in a statistically significant reduction in HbA1c compared with placebo (see Table 4).”
- 7.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.2
“Starting Dosage (Initiation Phase) (Days 1 to 30): The recommended starting dosage is 3 mg orally once daily (this dosage is not effective for glycemic control).”
- 8.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 14.1
“has been established as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus based on adequate and well-controlled studies of RYBELSUS in adult patients with type 2 diabetes mellitus”
- 9.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
“RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis.”
- 10.FDA label (DailyMed): Trulicity prescribing information, section 14.3
“At the 26-week placebo-controlled time point, the HbA1c change was 0.1%, -1.0%, -1.2%, and -0.6% for placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and sitagliptin, respectively.”
- 11.FDA label (DailyMed): Trulicity prescribing information, section 14.3, Table 6
“Table 6. Results at Week 36 of TRULICITY 1.5 mg Compared to 3 mg and 4.5 mg as Add-On to Metformin in Adult Patients with Type 2 Diabetes Mellitus. HbA1c (%) (Mean) - Change from baseline: TRULICITY 1.5 mg: -1.5; TRULICITY 3 mg: -1.6; TRULICITY 4.5 mg: -1.8”
- 12.FDA label (DailyMed): Mounjaro prescribing information, section 8.4
“The safety and effectiveness of MOUNJARO have not been established in pediatric patients less than 10 years of age.”
- 13.FDA label (DailyMed): Trulicity prescribing information, section 8.4
“The safety and effectiveness of TRULICITY have not been established in pediatric patients less than 10 years of age.”
- 14.FDA label (DailyMed): Mounjaro prescribing information, section 7.1
“When initiating MOUNJARO, consider reducing the dose of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.3)].”
- 15.FDA label (DailyMed): Ozempic prescribing information, section 7.1
“When initiating OZEMPIC, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia”
- 16.FDA label (DailyMed): Ozempic prescribing information, section 14.3
“OZEMPIC was superior to placebo in reducing the incidence of the primary composite endpoint of a sustained decline in eGFR of ≥50%, sustained eGFR <15 mL/min/1.73m2, chronic renal replacement therapy, renal death, CV death (HR 0.76 [95% CI 0.66, 0.88], p=0.0003) as shown in Table 10 and Figure 7.”
- 17.FDA label (DailyMed): Wegovy prescribing information, section 8.6
“Administration of WEGOVY injection resulted in less weight reduction in patients with type 2 diabetes and obesity or overweight compared to those without type 2 diabetes and obesity or overweight”
- 18.FDA label (DailyMed): Wegovy prescribing information, section 14.2, Table 8
“Study 3 was a 68-week trial that enrolled 807 patients with type 2 diabetes and BMI greater than or equal to 27 kg/m2.”
- 19.FDA label (DailyMed): Zepbound prescribing information, section 14.1, Table 2
“Table 2: Changes in Body Weight at Week 72 in Studies 1 and 2 in Patients with Obesity or Overweight. % Change from baseline: Study 1 Placebo N = 643: -3.1; Study 1 ZEPBOUND 5 mg N = 630: -15.0; Study 1 ZEPBOUND 10 mg N = 636: -19.5; Study 1 ZEPBOUND 15 mg N = 630: -20.9; Study 2 Placebo N = 315: -3.2; Study 2 ZEPBOUND 10 mg N = 312: -12.8; Study 2 ZEPBOUND 15 mg N = 311: -14.7”
- 20.Eli Lilly: Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
“Based on these findings, as well as those from ACHIEVE-1 and ACHIEVE-4, Lilly plans to submit Foundayo for the treatment of type 2 diabetes to the U.S. FDA by the end of the second quarter under the Commissioner's National Priority Review Voucher. [...] Foundayo (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity.”
- 21.CMS: Information for Part D Plans
“Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
- 22.CMS: Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-P)
“Since the inception of the Part D program, CMS has interpreted the statutory exclusion of “agents when used for weight loss” to mean that a drug, when used for weight loss, is excluded from the definition of a covered Part D drug. This historical interpretation does not distinguish between use of a drug for treatment of individuals with obesity and individuals without obesity. Therefore, under current policy, anti-obesity medications are only coverable in Part D if the drug is being used to treat another condition that is a medically accepted indication other than weight loss or weight management (for example, type 2 diabetes or to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight).”
- 23.
- 24.
- 25.
- 26.
Related pages
- GLP-1 drugs list: every brand, its generic name and what it is approved for
- Mounjaro (tirzepatide): uses, cost, doses and side effects
- What is Ozempic? Uses, doses, cost and how to take it
- Rybelsus (semaglutide tablets): uses, doses, cost and how to take it
- What is Trulicity (dulaglutide)? Uses, doses, cost and side effects
- Does Medicare cover GLP-1 medicines?
